Ciclosporin
Synonyms: cyclosporine, cyclosporin, cyclosporine A
Tags:
drug
small molecule
PubChem: 5284373 5284373 Related interactions
Related publications
Title
Author
Type
Potential SARS-CoV-2 protease Mpro inhibitors: repurposing FDA-approved drugs Valentina Kouznetsova, David Huang, Igor F. Tsigelny
Research
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Jeon, Sangeun and Ko, Meehyun and Lee, Jihye and Choi, Inhee and Byun, Soo Young and Park, Soonju and Shum, David and Kim, Seungtaek
Research
A Study of Potential SARS-CoV-2 Antiviral Drugs and Preliminary Research of Their Molecular Mechanism, Based on Anti-SARS-CoV Drug Screening and Molecular Dynamics Simulation Xiaomeng Zhao, Ruixia Liu, Zhi Miao, Nan Ye, Wenyu Lu
Research
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2 Andrés Pizzorno, Blandine Padey, Julia Dubois, Thomas Julien, Aurélien Traversier, Victoria Dulière, Pauline Bruna, Bruno Lina, Manuel Rosa-Calatrava, Olivier Terriera
Other
Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach Sinead M. O’Donovan, Ali Imami, Hunter Eby, Nicholas D. Henkel, Justin Fortune Creeden, Sophie Asah, Xiaolu Zhang, Xiaojun Wu, Rawan Alnafisah, R. Travis Taylor, James Reigle, Alexander Thorman, Behrouz Shamsaei, Jarek Meller, Robert E. McCullumsmith
Research
Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2 Mark Dittmar, Jae Seung Lee, Kanupriya Whig, Elisha Segrist, Minghua Li, Kellie Jurado, Kirandeep Samby, Holly Ramage, David Schultz, Sara Cherry
Research
Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19 Brian L. Le, Gaia Andreoletti, Tomiko Oskotsky, Albert Vallejo-Gracia, Romel Rosales, Katharine Yu, Idit Kosti, Kristoffer E. Leon, Daniel G. Bunis, Christine Li, G. Renuka Kumar, Kris M. White, Adolfo García-Sastre, Melanie Ott, Marina Sirota
Research
Comparison of viral RNA–host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Zhang, ShaojunHuang, WenzeRen, LiliJu, XiaohuiGong, MingliRao, JianSun, LeiLi, PanDing, QiangWang, JianweiZhang, Qiangfeng Cliff
Research
Target
Target affiliation
Drug
Type
Result
Target
Target affiliation
Drug
Type
Result
Name
Synonyms
Genes
Origin
Name
Synonyms
Genes
Origin
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Title
Authors
DOI
Source
Article type
Date
Title
Authors
DOI
Source
Article type
Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID.
It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial
